JTB, or Jumping Translocation Breakpoint, is a protein that has garnered interest in the field of genetics and cellular biology due to its unique role in cellular homeostasis and chromosomal stability. The protein is so named because of its involvement in translocations where parts of one chromosome jump to another, which can be a hallmark of various types of cancer. JTB is integral to the regulation of cellular growth and division, acting as a mediator in signaling pathways that control these processes. It is thought to interact with components of the cell's machinery that manage cellular stress and respond to growth signals, making it a critical player in maintaining the balance between cell survival and apoptosis, or programmed cell death. The proper functioning of JTB is crucial for ensuring that cells do not proliferate uncontrollably, a state which could lead to tumor development and progression.
Inhibiting JTB involves targeting this protein to disrupt its normal function, which can lead to the suppression of undesirable cellular proliferation and the potential restoration of normal cellular division and death processes. Mechanisms of inhibition can include small molecule inhibitors that bind directly to JTB, interfering with its ability to interact with other proteins or with DNA, thereby preventing it from carrying out its normal regulatory functions. Another method of inhibition might involve the use of antisense oligonucleotides or RNA interference strategies, which reduce the expression of the JTB gene, thus lowering the levels of the protein within the cell. These approaches aim to disrupt the pathways in which JTB is involved, particularly those related to the cell cycle and apoptosis. By inhibiting JTB, researchers aim to restore normal cellular control mechanisms that may be disrupted in diseases such as cancer. Moreover, exploring the inhibition of JTB could provide insights into the broader mechanisms of chromosomal stability and the cellular response to genetic stressors, contributing to a deeper understanding of cellular dynamics and disease pathology.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Targets mTOR pathway by inhibiting mTORC1. This affects the Akt pathway, leading to a decrease in JTB phosphorylation and function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK1, consequently suppressing the ERK pathway. Alters JTB's interaction with caspases, affecting its role in apoptosis. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, dampening the PI3K/Akt/mTOR axis and reducing JTB phosphorylation, affecting its stability and function. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Targets MDM2-p53 interaction. Upregulates p53, affecting JTB's role in p53-dependent apoptosis. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Targets MEK1 and MEK2. Dampens the MAPK/ERK pathway, subsequently reducing JTB's interaction with JNK pathways in apoptosis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, thereby disrupting the PI3K/Akt pathway. Reduces JTB phosphorylation and its interaction with anti-apoptotic factors. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB inhibitor, disrupts JTB's influence on pro-inflammatory genes, which can indirectly modulate apoptosis. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, affecting JTB’s ability to act as a scaffold protein in the JNK signaling pathway during apoptosis. | ||||||
Obatoclax Mesylate | 803712-79-0 | sc-364221 sc-364221A | 5 mg 10 mg | $96.00 $141.00 | ||
Inhibits Bcl-2 family proteins. Reduces JTB's interaction with Bcl-2, affecting its anti-apoptotic function. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
Inhibits GSK3β, affecting Wnt signaling. Alters JTB's role in β-catenin regulation. | ||||||